Загрузка...
Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma
Intravenous brentuximab vedotin (ADCETRIS(®)) is a targeted antibody-drug conjugate (ADC) active against CD30-positive cancer cells such as those associated with classical Hodgkin lymphoma (HL). In noncomparative, phase 2 trials and in the real-world setting, salvage therapy with brentuximab vedotin...
Сохранить в:
| Опубликовано в: : | Drugs |
|---|---|
| Главный автор: | |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer International Publishing
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7102329/ https://ncbi.nlm.nih.gov/pubmed/28190142 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-017-0705-5 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|